Allos Therapeutics (ALTH) Tops Q4 EPS by 6c

Allos Therapeutics (NASDAQ: ALTH) reported Q4 EPS of ($0.01), $0.06 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.94 million.

For earnings history and earnings-related data on Allos Therapeutics (ALTH) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c